RNS Number : 4507P
Genedrive PLC
10 June 2020

genedrive plc
("genedrive" or the "Company")

Investor presentation

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, is pleased to announce that David Budd, Chief Executive Officer, will be presenting at an investor webinar being hosted jointly by Turner Pope Investments (TPI) Ltd and Vox Markets.

The event will be held on Friday, 12 June 2020 at 2pm. Please register your interest at https://voxmarkets.brand.live/c/genedrive-plc.

genedrive plc +44 (0)161 989 0245
David Budd: CEO / Matthew Fowler: CFO

Peel Hunt LLP (Nominated Adviser and Joint Broker) +44 (0)20 7418 8900
James Steel / Oliver Jackson

finnCap (Joint Broker) +44 (0)20 7220 0500
Geoff Nash / Kate Bannatyne / Alice Lane

Walbrook PR Ltd (Media & Investor Relations) +44 (0)20 7933 8780 or genedrive@walbrookpr.com
Paul McManus / Anna Dunphy +44 (0)7980 541 893 / +44 (0)7876 741 001

About genedrive plc (http://www.genedriveplc.com)
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The Company recently launched a high throughput SARS-CoV-2 assay and has a Genedrive® Point of Care version of the assay in development, both based on Genedrive® PCR chemistry.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAFLFIRRFIAIII